Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler(University College London), Bergur V. Stefánsson(AstraZeneca (Sweden)), Niels Jongs(University of Groningen), Glenn M. Chertow(Stanford University), Tom Greene(University of Utah), Fan Fan Hou(Southern Medical University), John J.V. McMurray(University of Glasgow), Ricardo Correa‐Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Peter Rossing(University of Copenhagen), Robert D. Toto(The University of Texas Southwestern Medical Center), C. David Sjöström(AstraZeneca (Sweden)), Anna Maria Langkilde(AstraZeneca (Sweden)), Hiddo J.L. Heerspink(University of Groningen)
Cited by 526Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis